menu
    • menu

    Company profile for Denali Therapeutics

    NEW Drugs in Dev: 16
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Denali was founded by scientists, drug developers and investors who share the vision that recent scientific insights in genetics, biology and translational medicine offer an unprecedented opportunity to discover and develop effective medicines for patients suffering from neurodegenerative disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Denali TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    151 Oyster Point Blvd - South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.denalitherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Denali CEO Celebrates Launch Of Rare Disease Drug
    Denali CEO Celebrates Launch Of Rare Disease Drug

    22 Apr 2026

    // BIOSPACE

    https://www.biospace.com/business/denali-ceos-greatest-professional-moment-arrives-as-rare-disease-drug-launches

    BIOSPACE
    22 Apr 2026
    Share Share
    Takeda Ends Partnership With Veritas In Silico For mRNA-Targeting
    Takeda Ends Partnership With Veritas In Silico For mRNA-Targeting

    15 Apr 2026

    // BIOSPACE

    https://www.biospace.com/business/takeda-continues-to-prune-partnerships-cuts-ties-with-mrna-targeting-veritas-in-silico

    BIOSPACE
    15 Apr 2026
    Share Share
    Denali Regains Full Rights to Investigational Therapy DNL593
    Denali Regains Full Rights to Investigational Therapy DNL593

    03 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/03/3268105/0/en/Denali-Therapeutics-Regains-Full-Rights-to-Investigational-Therapy-DNL593-PTV-PGRN-for-GRN-related-Frontotemporal-Dementia-FTD-GRN.html

    GLOBENEWSWIRE
    03 Apr 2026
    Share Share
    Denali Delivers ‘Welcome Positive’ for Rare Disease Space
    Denali Delivers ‘Welcome Positive’ for Rare Disease Space

    26 Mar 2026

    // BIOSPACE

    https://www.biospace.com/fda/denali-delivers-welcome-positive-for-rare-disease-space-with-fdas-hunter-syndrome-nod

    BIOSPACE
    26 Mar 2026
    Share Share
    US FDA approves Denali's genetic disorder therapy for children
    US FDA approves Denali's genetic disorder therapy for children

    25 Mar 2026

    // PRESS RELEASE

    https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-us-fda-approval-avlayahtm

    PRESS RELEASE
    25 Mar 2026
    Share Share
    Denali’s Biologics Avlayah Receives Approval in US
    Denali’s Biologics Avlayah Receives Approval in US

    24 Mar 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761485

    FDA
    24 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search